Cosmo announces regulatory approval of GI GENIUS™ in Israel
Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that GI Genius™ has received regulatory approval in Israel.
GI Genius™ is the first system using artificial intelligence to detect colorectal polyps and is already available in Europe.
Cosmo recently announced very positive results of the first investigator initiated prospective clinical study of its GI Genius™ artificial intelligence endoscopy device. In this trial the system increased adenoma detection rate by an absolute value of 16% from 40.9% in the control arm to 56.9% in the GI Genius™ group. For more information regarding the GI Genius™ investigator initiated trial please visit: https://www.cosmopharma.com/news-and-media/press-releases-and-company-news/2020/200220